Oculis Holding AG (OCS) Gains from Investment Securities (2023 - 2026)
Oculis Holding AG's (OCS) quarterly Gains from Investment Securities came in at $10.2 million in Q1 2026, down 23.05% year-on-year from $13.2 million in Q1 2025, and up 150.86% quarter-over-quarter from $4.1 million in Q4 2025.
Oculis Holding AG (OCS) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Oculis Holding AG's Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $10.2 million for Q1 2026.
- On a quarterly basis, Gains from Investment Securities fell 23.05% year-over-year to $10.2 million in Q1 2026; TTM through Mar 2026 was $10.7 million, a 61.25% decrease from a year earlier, with the FY2025 full-year figure at $14.8 million, down 16.01% from the prior year.
- Gains from Investment Securities climbed to $10.2 million in Q1 2026 per OCS's latest filing, from $4.1 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $15.3 million in Q4 2024 and bottomed at -$3.9 million in Q3 2025.
- The 4-year median for Gains from Investment Securities is $2.8 million (2023), against an average of $3.5 million.
- Across the five-year window, Gains from Investment Securities jumped 1223.05% in 2024 and sank 854.27% in 2025, its largest moves.
- Year by year, Gains from Investment Securities stood at -$1.4 million in 2023, then soared by 1223.05% to $15.3 million in 2024, then slumped by 73.41% to $4.1 million in 2025, then soared by 150.86% to $10.2 million in 2026.
- Per Business Quant, the three latest OCS Gains from Investment Securities figures stand at $10.2 million (Q1 2026), $4.1 million (Q4 2025), and -$3.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.19 Mn |
| Mar 31, 2026 | 10.19 Mn |
| Dec 31, 2025 | 4.06 Mn |
| Dec 31, 2025 | 4.06 Mn |
| Sep 30, 2025 | -3.87 Mn |
| Sep 30, 2025 | -3.87 Mn |
| Jun 30, 2025 | 282,646.31 |
| Jun 30, 2025 | 282,646.31 |
| Mar 31, 2025 | 13.25 Mn |
| Mar 31, 2025 | 13.25 Mn |
| Dec 31, 2024 | 15.28 Mn |
| Dec 31, 2024 | 15.28 Mn |
| Sep 30, 2024 | 513,622.22 |
| Sep 30, 2024 | 513,622.22 |
| Jun 30, 2024 | -1.51 Mn |
| Jun 30, 2024 | -1.51 Mn |
| Mar 31, 2024 | 3.52 Mn |
| Mar 31, 2024 | 3.52 Mn |
| Dec 31, 2023 | -1.36 Mn |
| Dec 31, 2023 | -1.36 Mn |